Prime Medicine, Inc.

Prime Medicine, Inc.

PRME·NASDAQ

$3.21

-2.2%
HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$579.78M
EPS-1.3500
P/E Ratio-2.57
Earnings Date08/06/2026

prme

Total Payables

Last Annual Value

8.89M

3-Year CAGR

27%

5-Year CAGR

104%

10-Year CAGR

%

Prime Medicine, Inc.

Prime Medicine, Inc. Competitors Analysis of Total Payables

PRME · NASDAQ
CompanyTotal Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
8.89M
-23.1%44.0%N/A 
PROK logo
ProKidney Corp.
NASDAQ:PROK
940.00K
-47.7%-19.8%N/A
5.26M
31.7%10.2%23.5%
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
10.28M
53.6%N/AN/A
34.88M
75.0%36.4%42.4%
12.46M
32.4%39.5%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
5.81M
21.1%41.2%14.5%
0.00
N/AN/AN/A
1.18M
-36.8%14.5%N/A
9.80M
15.7%-38.3%N/A
5.51M
20.1%N/AN/A
Prime Medicine, Inc.

Prime Medicine, Inc. Fair Value Envelope

PRME · NASDAQ

Our analysis suggests that PRME has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.21, this represents a potential HIDDEN relative to our calculated worth for Prime Medicine, Inc..

Intrinsic Value
Current Price: $3.21